A well-intentioned drug pricing reform under the Inflation Reduction Act (IRA) could lead to higher out-of-pocket costs and serious health risks for Medicare patients—despite its goal to lower drug prices. The post Lower Prices, Higher Risk: How Drug Reform Could Backfire on Patients appeared first on CreakyJoints.
